"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves nivolumab (Opdivo) as Adjuvant Therapy in Patients with Completely Resected Melanoma

08 Jan 2018 2:32 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (Opdivo; Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software